Joshua A. Kazam - 18 Dec 2025 Form 4 Insider Report for Allogene Therapeutics, Inc. (ALLO)

Role: Director
Signature: /s/Earl Douglas, Attorney-in-Fact
Issuer symbol: ALLO
Transactions as of: 18 Dec 2025
Net transactions value: $0
Form type: 4
Filing time: 22 Dec 2025, 18:57:11 UTC
Previous filing: 20 Jun 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Kazam Joshua A	Director	210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO	/s/Earl Douglas, Attorney-in-Fact	22 Dec 2025	0001221355

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ALLO	Common Stock	Options Exercise	$0	+47,700	+16%	$0.000000	350,763	18 Dec 2025	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ALLO	Restricted Stock Unit	Options Exercise	$0	-47,700	-50%	$0.000000	47,700	18 Dec 2025	Common Stock	47,700		Direct	F1, F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On June 23, 2025, this grant was erroneously reported as 94,500 shares and is corrected here upon the vesting of the first of the semi-annual installments.
F2	Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2018 Plan.
F3	Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date.